Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer

David J. Sher, Mary Jo Fidler, Michael J. Liptay, Matthew Koshy

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: The optimal neoadjuvant therapy prior to surgical resection of stage IIIA non-small cell lung cancer (NSCLC) is controversial, as data support both preoperative chemoradiotherapy (N-CRT) and chemotherapy (N-CTX). We evaluated the comparative effectiveness of N-CRT versus N-CTX in stage IIIA patients in the National Cancer Database (NCDB). Methods: Patients in the NCDB with stage IIIA NSCLC treated with N-CRT or N-CTX and surgery between 2003 and 2005 were analyzed. Outcomes included overall survival (OS), residual nodal disease (RND), any adverse pathologic features (APF = RND or positive margins), and 30-day postoperative mortality (POPM). The survival impact of post-operative radiotherapy (PORT) after N-CTX was also investigated. Results: The cohort consisted of 1076 patients: 700 (65%) underwent N-CRT. The 5-year OS for the entire cohort was 39% (39.2% N-CRT vs. 38.6% N-CTX, p= NS). On multivariable regression, there was no difference in OS between N-CRT versus N-CTX (p= 0.70). However, N-CRT was associated with a lower independent risk of RND (odds ratio, OR, 0.75, p= 0.02) and a lower risk of APF (OR 0.67, p= 0.0023). Among N-CTX patients, PORT was associated with inferior survival in patients without APF (hazard ratio 1.68, p= 0.01) but not with APF. N-CRT did not increase early POPM, readmission rates, or length of stay. Conclusion: There was no difference in overall survival between these two strategies, although N-CRT was associated with improved pathologic outcomes. These data support either treatment approach, but early surgical consultation is critical to ensure operability. The indications for PORT in patients without adverse pathologic factors require further investigation.

Original languageEnglish (US)
Pages (from-to)267-274
Number of pages8
JournalLung Cancer
Volume88
Issue number3
DOIs
StatePublished - Jun 1 2015

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Drug Therapy
Survival
Radiotherapy
Databases
Neoadjuvant Therapy
Mortality
Length of Stay
Neoplasms
Referral and Consultation
Odds Ratio

Keywords

  • Combined modality therapy
  • Comparative effectiveness
  • NSCLC
  • Radiotherapy

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. / Sher, David J.; Fidler, Mary Jo; Liptay, Michael J.; Koshy, Matthew.

In: Lung Cancer, Vol. 88, No. 3, 01.06.2015, p. 267-274.

Research output: Contribution to journalArticle

@article{7d081617601f45c5aaa73b191d52d824,
title = "Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer",
abstract = "Objectives: The optimal neoadjuvant therapy prior to surgical resection of stage IIIA non-small cell lung cancer (NSCLC) is controversial, as data support both preoperative chemoradiotherapy (N-CRT) and chemotherapy (N-CTX). We evaluated the comparative effectiveness of N-CRT versus N-CTX in stage IIIA patients in the National Cancer Database (NCDB). Methods: Patients in the NCDB with stage IIIA NSCLC treated with N-CRT or N-CTX and surgery between 2003 and 2005 were analyzed. Outcomes included overall survival (OS), residual nodal disease (RND), any adverse pathologic features (APF = RND or positive margins), and 30-day postoperative mortality (POPM). The survival impact of post-operative radiotherapy (PORT) after N-CTX was also investigated. Results: The cohort consisted of 1076 patients: 700 (65{\%}) underwent N-CRT. The 5-year OS for the entire cohort was 39{\%} (39.2{\%} N-CRT vs. 38.6{\%} N-CTX, p= NS). On multivariable regression, there was no difference in OS between N-CRT versus N-CTX (p= 0.70). However, N-CRT was associated with a lower independent risk of RND (odds ratio, OR, 0.75, p= 0.02) and a lower risk of APF (OR 0.67, p= 0.0023). Among N-CTX patients, PORT was associated with inferior survival in patients without APF (hazard ratio 1.68, p= 0.01) but not with APF. N-CRT did not increase early POPM, readmission rates, or length of stay. Conclusion: There was no difference in overall survival between these two strategies, although N-CRT was associated with improved pathologic outcomes. These data support either treatment approach, but early surgical consultation is critical to ensure operability. The indications for PORT in patients without adverse pathologic factors require further investigation.",
keywords = "Combined modality therapy, Comparative effectiveness, NSCLC, Radiotherapy",
author = "Sher, {David J.} and Fidler, {Mary Jo} and Liptay, {Michael J.} and Matthew Koshy",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2015.03.015",
language = "English (US)",
volume = "88",
pages = "267--274",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer

AU - Sher, David J.

AU - Fidler, Mary Jo

AU - Liptay, Michael J.

AU - Koshy, Matthew

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objectives: The optimal neoadjuvant therapy prior to surgical resection of stage IIIA non-small cell lung cancer (NSCLC) is controversial, as data support both preoperative chemoradiotherapy (N-CRT) and chemotherapy (N-CTX). We evaluated the comparative effectiveness of N-CRT versus N-CTX in stage IIIA patients in the National Cancer Database (NCDB). Methods: Patients in the NCDB with stage IIIA NSCLC treated with N-CRT or N-CTX and surgery between 2003 and 2005 were analyzed. Outcomes included overall survival (OS), residual nodal disease (RND), any adverse pathologic features (APF = RND or positive margins), and 30-day postoperative mortality (POPM). The survival impact of post-operative radiotherapy (PORT) after N-CTX was also investigated. Results: The cohort consisted of 1076 patients: 700 (65%) underwent N-CRT. The 5-year OS for the entire cohort was 39% (39.2% N-CRT vs. 38.6% N-CTX, p= NS). On multivariable regression, there was no difference in OS between N-CRT versus N-CTX (p= 0.70). However, N-CRT was associated with a lower independent risk of RND (odds ratio, OR, 0.75, p= 0.02) and a lower risk of APF (OR 0.67, p= 0.0023). Among N-CTX patients, PORT was associated with inferior survival in patients without APF (hazard ratio 1.68, p= 0.01) but not with APF. N-CRT did not increase early POPM, readmission rates, or length of stay. Conclusion: There was no difference in overall survival between these two strategies, although N-CRT was associated with improved pathologic outcomes. These data support either treatment approach, but early surgical consultation is critical to ensure operability. The indications for PORT in patients without adverse pathologic factors require further investigation.

AB - Objectives: The optimal neoadjuvant therapy prior to surgical resection of stage IIIA non-small cell lung cancer (NSCLC) is controversial, as data support both preoperative chemoradiotherapy (N-CRT) and chemotherapy (N-CTX). We evaluated the comparative effectiveness of N-CRT versus N-CTX in stage IIIA patients in the National Cancer Database (NCDB). Methods: Patients in the NCDB with stage IIIA NSCLC treated with N-CRT or N-CTX and surgery between 2003 and 2005 were analyzed. Outcomes included overall survival (OS), residual nodal disease (RND), any adverse pathologic features (APF = RND or positive margins), and 30-day postoperative mortality (POPM). The survival impact of post-operative radiotherapy (PORT) after N-CTX was also investigated. Results: The cohort consisted of 1076 patients: 700 (65%) underwent N-CRT. The 5-year OS for the entire cohort was 39% (39.2% N-CRT vs. 38.6% N-CTX, p= NS). On multivariable regression, there was no difference in OS between N-CRT versus N-CTX (p= 0.70). However, N-CRT was associated with a lower independent risk of RND (odds ratio, OR, 0.75, p= 0.02) and a lower risk of APF (OR 0.67, p= 0.0023). Among N-CTX patients, PORT was associated with inferior survival in patients without APF (hazard ratio 1.68, p= 0.01) but not with APF. N-CRT did not increase early POPM, readmission rates, or length of stay. Conclusion: There was no difference in overall survival between these two strategies, although N-CRT was associated with improved pathologic outcomes. These data support either treatment approach, but early surgical consultation is critical to ensure operability. The indications for PORT in patients without adverse pathologic factors require further investigation.

KW - Combined modality therapy

KW - Comparative effectiveness

KW - NSCLC

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84929514072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929514072&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2015.03.015

DO - 10.1016/j.lungcan.2015.03.015

M3 - Article

C2 - 25862147

AN - SCOPUS:84929514072

VL - 88

SP - 267

EP - 274

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -